Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are: * What is the safety and tolerability profile of WBC100 in R/R AML patients? * Can WBC100 effectively induce remission in R/R AML patients? Participants will: * Take WBC100 capsules orally once daily in 28-day treatment cycles; * Undergo regular safety assessments, including adverse event monitoring and laboratory tests; * Provide blood samples for pharmacokinetic (PK) analysis; * Have their remission status and efficacy evaluated according to the ELN2022 criteria.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Rozpoznana nawrotowa lub oporna ostra białaczka mieloidalna
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-2)
- •Przewidywana długość życia co najmniej 3 miesiące
- •Prawidłowa funkcja wątroby, nerek i serca
- •Liczba białych krwinek we krwi poniżej 25 × 10⁹/L
- •Dla kobiet w wieku rozrodczym: skuteczna antykoncepcja przez leczenie i 6 miesięcy po
✗ Disqualifies
- •Alergia na WBC100 lub jego składniki
- •Akutna białaczka promieloblastyczna
- •Przeszczep szpiku w ciągu ostatnich 90 dni
- •Poważne działania niepożądane po poprzednim przeszczepie szpiku
- •Duża operacja, niezagojone rany lub wrzody w ciągu 28 dni przed badaniem
- •Inne badawcze leki w ciągu ostatnich 28 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Trial contact
Wu Shuigao, M.S
Zheng Meng, PM
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.